CD274 and non-small cell lung carcinoma: Most recently, EGFR inhibitors have been shown to down-modulate baseline PD-L1 expression, a prominent immune-checkpoint protein, on selected non-small cell lung cancer cell lines with sensitive EGFR mutations that expressed high baseline level of PD-L1 proteins [20–22].